在减重方面,与安慰剂相比,tirzepatide是最有效的药物,尤其是tirzepatide 15mg组,可使体重减少9.57kg;而semaglutide的效果则较弱,2.0mg组仅能减少4.97kg,0.5mg组更是只有2.52kg。
P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503–515 (2021). Article PubMed Google Scholar Ludvik, B. et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 ...
doi:10.1016/S0140-6736(21)00213-0 PubMedGoogle ScholarCrossref 8. Garvey WT, Batterham RL, Bhatta M, et al; STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038...
Methods: PubMed, Ovid/Medline, Web of Science, Scopus,... M Kanbay,S Copur,D Siriopol,... - 《Diabetes Obesity & Metabolism》 被引量: 0发表: 2023年 Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test CONTEXT. In a ...
New incretin-based, antiobesity medications could bolster the results of intensive lifestyle intervention20. Semaglutide 2.4 mg is a glucagon-like peptide-1 (GLP-1) receptor agonist, originally approved at a lower dose for control of type 2 diabetes and which, in persons with obesity or ove...
doi:10.4158/EP161365.GLPubMedGoogle ScholarCrossref 5. Rubino D, Abrahamsson N, Davies M, et al; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial...
Most recently, we also examined the US population impact of subcutaneous semaglutide 2.4 mg, identifying 93 million US adults with overweight or obesity to be eligible based on STEP 1 trial eligibility criteria, with up to a 1.8% absolute (17.8% relative) CVD risk reduction projected that ...
In contrast, 1 mM metformin and the MS combination had similar effects on NKX6.1 protein levels, which were comparable to the Ct group and lower than both HG-HL+Med and 10 nM semaglutide treatments (Figure 5B(b)). 3. Discussion Obesity contributes to the dysfunction and reduction in the ...
TZP versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N. Engl. J. Med. 2021, 385, 503–515. [Google Scholar] [CrossRef] Ludvik, B.; Giorgino, F.; Jódar, E.; Frias, J.P.; Fernández Landó, L.; Brown, K.; Bray, R.; Rodríguez, Á. Once-weekly TZP versus ...